Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter Open Access June 12, 2013

Progressive course of isolated splenic myeloid sarcoma

  • Darko Antic EMAIL logo , Maja Perunicic Jovanovic , Djordje Knezevic , Slavenko Ostojic and Ivo Elezovic
From the journal Open Medicine

Abstract

A previously healthy 40-year-old male presented with a 2-week history of fever and abdominal discomfort that was resistant to empirical broad-spectrum antibiotic treatment. The patient’s blood cell count and complete biochemical panel was normal, except for an increased lactate dehydrogenase level. Ultrasonography and computed tomography of the abdomen showed a large, soft tissue mass had infiltrated superior part of the spleen. Splenectomy with total tumor mass removal were performed. The pathological examination of the tumor tissue confirmed diagnosis of isolated myeloid sarcoma with monoblastic differentiation. Despite intensive antileukemic therapy, patient died four months after diagnosis was established.

[1] Pileri SA, Orayi A, Falini B: Myeloid sarcoma. In Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO classification of tumours of haematopoetic and lymphoid tissues. Lyon, IARC, 2008, pp 140–141 Search in Google Scholar

[2] Burns A. Observation of surgical anatomy, head and neck. Edinburgh: Thomas Royce and co;1811, pp 364–366 Search in Google Scholar

[3] King A. A case of chloroma. Monthly J med 1853;17:97 Search in Google Scholar

[4] Rappaport H. Tumors of the hematopoetic system. Armed Forces Inst Pathol 1966; 241–243 Search in Google Scholar

[5] Hutchinson RE, Kurec AS, Davey FR. Granulocytic sarcoma. Clin Lab Med. 1990; 10; 889–901 Search in Google Scholar

[6] Paydas S, Zorludemir S, Ergin M. Granulocytic sarcoma: 32 cases and review of the literature. Leuk Lymphoma. 2006; 47(12) 10.1080/10428190600967196Search in Google Scholar

[7] Antic D, Verstovsek S, Elezovic I, Grujicic D, Gotic M, Bila J et al. Spinal epidural granulocytic sarcoma in non-leukemic patient. Int J Hematol. 2009 Jan;89(1):95–97 http://dx.doi.org/10.1007/s12185-008-0227-810.1007/s12185-008-0227-8Search in Google Scholar

[8] Antic D, Elezovic I, Bogdanovic A, Vukovic NS, Pavlovic A, Jovanovic MP Isolated myeloid sarcoma of the gastrointestinal tract. Intern Med. 2010;49(9):853–856 http://dx.doi.org/10.2169/internalmedicine.49.287410.2169/internalmedicine.49.2874Search in Google Scholar

[9] Audouin J, Comperat E, Le Tourneau A, Camilleri-Broët S, Adida C, Molina T et al. Myeloid sarcoma: clinical and morphologic criteria useful for diagnosis Int J Surg Pathol. 2003; 11(4):271–282 http://dx.doi.org/10.1177/10668969030110040410.1177/106689690301100404Search in Google Scholar

[10] Alexiev BA, Wang W, Ning Y, Chumsri S, Gojo I, Rodgers WH et al. Myeloid sarcomas: a histologic, immunohistochemical, and cytogenetic study. Diagn Pathol. 2007; 2:42 http://dx.doi.org/10.1186/1746-1596-2-4210.1186/1746-1596-2-42Search in Google Scholar

[11] Klco JM, Welch JS, Nguyen TT, Hurley MY, Kreisel FH, Hassan A et al. State of the art in myeloid sarcoma. Int J Lab Hematol. 2011;33(6):555–565 http://dx.doi.org/10.1111/j.1751-553X.2011.01361.x10.1111/j.1751-553X.2011.01361.xSearch in Google Scholar

[12] Breccia M, Mandelli F, Petti MC, D’Andrea M, Pescarmona E, Pileri SA et al. Clinicopathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution. Leuk Res. 2004; 28(11):1165–1169 http://dx.doi.org/10.1016/j.leukres.2004.01.02210.1016/j.leukres.2004.01.022Search in Google Scholar

[13] Rund D, Azar I, Shperling O. A mutation in the promoter of the multidrug resistance gene (MDR1) in human hematological malignancies may contribute to the pathogenesis of resistant disease. Adv Exp Med Biol. 1999;457:71–75 http://dx.doi.org/10.1007/978-1-4615-4811-9_910.1007/978-1-4615-4811-9_9Search in Google Scholar

[14] Bakst RL, Tallman MS, Douer D, Yahalom J. How I treat extramedullary acute myeloid leukemia. Blood. 2011;118(14):3785–3793 http://dx.doi.org/10.1182/blood-2011-04-34722910.1182/blood-2011-04-347229Search in Google Scholar

[15] Meis JM, Butler JJ, Osborne BM, Manning JT. Granulocytic sarcoma in nonleukemic patients. Cancer. 1986; 58(12):2697–2709 http://dx.doi.org/10.1002/1097-0142(19861215)58:12<2697::AID-CNCR2820581225>3.0.CO;2-R10.1002/1097-0142(19861215)58:12<2697::AID-CNCR2820581225>3.0.CO;2-RSearch in Google Scholar

[16] Byrd, J.C., Edenfield, W.J., Shields, D.J. and Dawson, N.A. Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: A Clinical Review J. Clin. Oncol. 1995; 13(7), 1800–1816 10.1200/JCO.1995.13.7.1800Search in Google Scholar

[17] Neiman RS, Barcos M, Berard C, Bonner H, Mann R, Rydell RE et al. Granulocytic sarcoma: a clinicopathologic study of 61 biopsed cases. Cancer 1981;48: 1426–1437 http://dx.doi.org/10.1002/1097-0142(19810915)48:6<1426::AID-CNCR2820480626>3.0.CO;2-G10.1002/1097-0142(19810915)48:6<1426::AID-CNCR2820480626>3.0.CO;2-GSearch in Google Scholar

[18] Yamauchi K, Yasuda M. Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature. Cancer. 2002; 94(6):1739–1746 http://dx.doi.org/10.1002/cncr.1039910.1002/cncr.10399Search in Google Scholar

[19] Tsimberidou AM, Kantarjian HM, Wen S, Keating MJ, O’Brien S, Brandt M et al. Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer. 2008; 113(6):1370–1378 http://dx.doi.org/10.1002/cncr.2369110.1002/cncr.23691Search in Google Scholar

[20] Pileri SA Ascani S, Cox MC, Campidelli C, Bacci F, Piccioli M et al. Myeloid sarcoma: clinico pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia. 2007; 21(2):340–350 http://dx.doi.org/10.1038/sj.leu.240449110.1038/sj.leu.2404491Search in Google Scholar

[21] Lan TY, Lin DT, Tien HF, Yang RS, Chen CY, Wu K. Prognostic factors of treatment outcomes in patients with granulocytic sarcoma. Acta Haematol. 2009;122(4):238–246 http://dx.doi.org/10.1159/00025359210.1159/000253592Search in Google Scholar

[22] Antic D, Elezovic I, Milic N, Suvajdzic N, Vidovic A, Perunicic M et al. Is there a “gold” standard treatment for patients with isolated myeloid sarcoma? Biomed Pharmacother. 2013;67(1):72–77 http://dx.doi.org/10.1016/j.biopha.2012.10.01410.1016/j.biopha.2012.10.014Search in Google Scholar

[23] Chevallier P, Labopin M, Cornelissen J, Socié G, Rocha V, Mohty M; ALWP of EBMT. Allogeneic hematopoietic stem cell transplantation for isolated and leukemic myeloid sarcoma in adults: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation. Haematologica.2011;96(9):1391–1394 http://dx.doi.org/10.3324/haematol.2011.04141810.3324/haematol.2011.041418Search in Google Scholar

Published Online: 2013-6-12
Published in Print: 2013-8-1

© 2013 Versita Warsaw

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Downloaded on 28.3.2024 from https://www.degruyter.com/document/doi/10.2478/s11536-013-0161-x/html
Scroll to top button